Test the hypothesis that chronic MitoQ supplementation in breast cancer patients treated with doxorubicin prevents:~increased mitochondrial oxidative stress;~the increase in cardiac markers (B-type natriuretic peptide and troponin I);~changes in left ventricular deformity (speckle tracking, strain) and reduction in LVEF;~endothelium-dependent dysfunction of peripheral vascular beds;~the increase in endothelial microvesicles;~the increase in material stiffness;~the elevation of central blood pressure.
Investigate the protective effect of chronic MitoQ supplementation on cardiovascular toxicity induced by doxorubicin-based adjuvant chemotherapy in breast cancer patients.